118 related articles for article (PubMed ID: 27079043)
1. Insurers, drugmakers wrestle with how to build value-based contracts.
Herman B
Mod Healthc; 2016 Feb; 46(8):12-3. PubMed ID: 27079043
[No Abstract] [Full Text] [Related]
2. US health reform: a mixed bag for insurers and drug companies.
Furlow B
Lancet Oncol; 2010 May; 11(5):417-8. PubMed ID: 20449872
[No Abstract] [Full Text] [Related]
3. Contract price integrity for pharmaceuticals.
Dunehew AR; Stokes H; Newberry J; Evangelista D
Am J Health Syst Pharm; 2005 Feb; 62(4):422-9. PubMed ID: 15745898
[No Abstract] [Full Text] [Related]
4. Value Tools Not in The Insurer Toolkit-Yet.
Silverman E
Manag Care; 2016 Oct; 25(10):16-17. PubMed ID: 28121538
[TBL] [Abstract][Full Text] [Related]
5. Can private Medicare health plans effectively compete with the government?
Twiss AK
Manag Care Interface; 2004 May; 17(5):25-6, 32. PubMed ID: 15217161
[No Abstract] [Full Text] [Related]
6. Vaccine finance resources for physicians.
Sobczyk E
Pediatrics; 2009 Dec; 124 Suppl 5():S573-6. PubMed ID: 19948594
[No Abstract] [Full Text] [Related]
7. The dynamics of power in health care.
Integr Healthc Rep; 1993 Nov; ():1-7. PubMed ID: 10131004
[No Abstract] [Full Text] [Related]
8. Stemming the risk of capitated contracts: what providers should consider when buying stop loss insurance.
Kreig J
Health Care Innov; 1995; 5(2):12-6. PubMed ID: 10150617
[TBL] [Abstract][Full Text] [Related]
9. Federal oversight of drug company--PBM alliances should continue, says GAO.
Am J Health Syst Pharm; 1996 Mar; 53(6):607, 610. PubMed ID: 8800961
[No Abstract] [Full Text] [Related]
10. Federal prime vendor project ready to ride.
Betz R
J Healthc Resour Manag; 1995 Aug; 13(8):34-5. PubMed ID: 10144864
[No Abstract] [Full Text] [Related]
11. Integrating care through bundled payments--lessons from The Netherlands.
Struijs JN; Baan CA
N Engl J Med; 2011 Mar; 364(11):990-1. PubMed ID: 21410368
[No Abstract] [Full Text] [Related]
12. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
Shen AK; Rodewald LE; Birkhead GS
Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
[TBL] [Abstract][Full Text] [Related]
13. Advisors may urge NIH to seek out industry support for clinical trials.
Appel A
Nature; 1995 Nov; 378(6553):116. PubMed ID: 7477301
[No Abstract] [Full Text] [Related]
14. Healthcare transition managers make market exits easier for insurers.
Resnick LR
Healthc Financ Manage; 1999 Oct; 53(10):39-41. PubMed ID: 11066665
[TBL] [Abstract][Full Text] [Related]
15. Shifting Gears: The Move Toward Value-Based Payment.
Wagner K
Healthc Exec; 2015; 30(3):10-2, 14-6, 18. PubMed ID: 26742339
[No Abstract] [Full Text] [Related]
16. MAG slays the dragon: the saga of HealthCare COMPARE.
Bailey JP; Taylor C
J Med Assoc Ga; 1991 Sep; 80(9):483-5. PubMed ID: 1744527
[No Abstract] [Full Text] [Related]
17. Disease management--promises and pitfalls.
Bodenheimer T
N Engl J Med; 1999 Apr; 340(15):1202-5. PubMed ID: 10202174
[No Abstract] [Full Text] [Related]
18. A vendor's guide to six managed care trends.
Scott L
Med Interface; 1997 Feb; 10(2):111-2, 114. PubMed ID: 10164787
[TBL] [Abstract][Full Text] [Related]
19. Medicare, Medicaid contracting.
Iglehart JK
Hosp Prog; 1978 Dec; 59(12):20. PubMed ID: 361538
[No Abstract] [Full Text] [Related]
20. Capitation risks for pharmacy services.
Navarro RP
Med Interface; 1994 Jul; 7(7):88-90. PubMed ID: 10135996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
